We selected this combination of antibody and nucleic acid TLR agonist since Trastuzumab is a monoclonal antibody with established clinical efficacy in cancer treatment and CpG ODN are more stable than RNA oligoribonucleotides (ORN) used as TLR7 agonists and are molecular defined unlike polymeric heterogeneous mixtures such as the TLR3 agonist polyI:C. The gene discussed is TLR7; the disease is cancer.